Orexigen Therapeutics (OREX) – Analyst Ratings
-
RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60
-
Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from Takeda
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to OREX Stock Lookup